Health Care News, Disease, Diagnose, Physicians, Residents, Medical Officers, Nursing Care, Technical Staff, Health Policies, Organizations, Certification, Standards, Alerts, and All about Worlds Health. Step to Facilitate the Health Care Professionals and Patients. Provide Safety and Quality to Patient's, Health Care staff, Explain Patient Family Education and Rights.

Link Between Bone Loss And Diuretics In Older Men

Categorie : Bones / Orthopaedics
According to a study published in the Archives of InternalMedicine, researchers have found increased rates of hip boneloss in older men who take frequently prescribed heart failure andhypertension drugs called loop diuretics.Study author Lionel S. Lim M.D., M.P.H. (Griffin Hospital, Derby,Conn.) and ...

read more According to a study published in the Archives of InternalMedicine, researchers have found increased rates of hip boneloss in older men who take frequently prescribed heart failure andhypertension drugs called loop diuretics.Study author Lionel S. Lim M.D., M.P.H. (Griffin Hospital, Derby,Conn.) and read more Sat Apr 2008 Sat Apr 2008

Bone Densitometers Market To Reach 698 Million Dollars In 2010, According To New Report By Global Industry Analysts

Categorie : Bones / Orthopaedics
Worldwide bone densitometers market is projected to reach $698 million by 2010 as stated in a recent report published by Global Industry Analysts, Inc. The alarming rise of osteoporosis has propelled the need for early detection of the disease. ...

read more Worldwide bone densitometers market is projected to reach $698 million by 2010 as stated in a recent report published by Global Industry Analysts, Inc. The alarming rise of osteoporosis has propelled the need for early detection of the disease. read more Sat Apr 2008 Sat Apr 2008

Stem Cell Research Leads To Potential New Therapy For Rare Blood Disorder

Categorie : Blood / Hematology
A unique partnership between industry and academia has led to human clinical trials of a new drug for a rare class of blood diseases called myeloproliferative disorders (MPD), which are all driven by the same genetic mutation and can evolve into leukemia. ...

read more A unique partnership between industry and academia has led to human clinical trials of a new drug for a rare class of blood diseases called myeloproliferative disorders (MPD), which are all driven by the same genetic mutation and can evolve into leukemia. read more Sat Apr 2008 Sat Apr 2008

Rep. Farr Requests That Policy Barring MSM From Donating Blood Be Re-Evaluated

Categorie : Blood / Hematology
Rep. Sam Farr (D-Calif.) on Wednesday requested that the fiscal year 2009 agriculture spending bill include language to require FDA to re-evaluate its policy preventing men who have sex with men from donating blood, Farr spokesperson Tom Mentzer said, CQ Today reports (Sternstein, CQ Today, 4/2). ...

read more Rep. Sam Farr (D-Calif.) on Wednesday requested that the fiscal year 2009 agriculture spending bill include language to require FDA to re-evaluate its policy preventing men who have sex with men from donating blood, Farr spokesperson Tom Mentzer said, CQ Today reports (Sternstein, CQ Today, 4/2). read more Sat Apr 2008 Sat Apr 2008

Neutropenia: Biosimilar Product From India Moves One Step Closer To European Market

Categorie : Blood / Hematology
A biosimilar product for treating the negative effects that cancer chemotherapy can have on the white blood cells of patients is safe and exhibits an identical pharmacokinetic and pharmacodynamic profile compared to a reference product. This is the result of a clinical phase I trial conduct ...

read more A biosimilar product for treating the negative effects that cancer chemotherapy can have on the white blood cells of patients is safe and exhibits an identical pharmacokinetic and pharmacodynamic profile compared to a reference product. This is the result of a clinical phase I trial conduct read more Sat Apr 2008 Sat Apr 2008

Intracranial Hemorrhage Patients Better Off After Having Blood Pressure Lowered Even More

Categorie : Blood / Hematology
Intracranial Hemorrhage Patients Better Off After Having Blood PressureLowered Even More An article in The Lancet Neurology suggests that inindividuals who have had intracranial hemorrhage, hematoma growth canbe reduced by lowering their blood pressure even further than whatexisting guidelines recom ...

read more Intracranial Hemorrhage Patients Better Off After Having Blood PressureLowered Even More An article in The Lancet Neurology suggests that inindividuals who have had intracranial hemorrhage, hematoma growth canbe reduced by lowering their blood pressure even further than whatexisting guidelines recom read more Sat Apr 2008 Sat Apr 2008

Interpreting Sign Language Places Greater Stress On Extremities Than Industrial Activities

Categorie : Body Aches
Sign language interpreting is one of the highest-risk professions for ergonomic injury, according to a new study conducted by Rochester Institute of Technology. The research indicates that interpreting causes more physical stress to the extremities than high-risk tasks conducted in industrial settin ...

read more Sign language interpreting is one of the highest-risk professions for ergonomic injury, according to a new study conducted by Rochester Institute of Technology. The research indicates that interpreting causes more physical stress to the extremities than high-risk tasks conducted in industrial settin read more Sat Apr 2008 Sat Apr 2008

PATHFAST(R): Rapid Whole Blood Immunoassay Analyzer From Polymedco

Categorie : Blood / Hematology
Polymedco, Inc. is pleased to announce the introduction of the PATHFAST immunoassay analyzer. The PATHFAST rapid point of care system utilizes a chemiluminescent technology combined with a unique magtration separation method that allows this system to report highly accurate results that compare to ...

read more Polymedco, Inc. is pleased to announce the introduction of the PATHFAST immunoassay analyzer. The PATHFAST rapid point of care system utilizes a chemiluminescent technology combined with a unique magtration separation method that allows this system to report highly accurate results that compare to read more Sat Apr 2008 Sat Apr 2008

EBMT Has Successful Finish To 34th EBMT Annual Congress, Plans For The Coming Year

Categorie : Blood / Hematology
The 34th Annual Congress of the European Group for Blood and Marrow Transplantation (EBMT) closed its session on the afternoon of 2 April 2008, wrapping up a successful five day Congress with a range of activities, informational sessions, and workshops. This years Congress had a record number of 4, ...

read more The 34th Annual Congress of the European Group for Blood and Marrow Transplantation (EBMT) closed its session on the afternoon of 2 April 2008, wrapping up a successful five day Congress with a range of activities, informational sessions, and workshops. This years Congress had a record number of 4, read more Sat Apr 2008 Sat Apr 2008

Too Much Of A Good Thing: High Levels Of Factor VIIa Cause Problems In Mice

Categorie : Blood / Hematology
Individuals with hemophilia lack either factor VIII or factor IX, proteins crucial for the cascade of events that leads to blood clotting. Although individuals with hemophilia can be treated by intravenous infusion of the factor that they miss, over time, some individuals develop antibodies that pre ...

read more Individuals with hemophilia lack either factor VIII or factor IX, proteins crucial for the cascade of events that leads to blood clotting. Although individuals with hemophilia can be treated by intravenous infusion of the factor that they miss, over time, some individuals develop antibodies that pre read more Sat Apr 2008 Sat Apr 2008

Protecting A Life-Saving Blood Product From Human Form Of Mad Cow Disease

Categorie : Blood / Hematology
Amid concern that recipients of certain blood transfusions may risk infection with a deadly protein responsible for the human form of mad cow disease, researchers in Canada now report development of a special filter that quickly and effectively removes the protein from blood.In addition to causing m ...

read more Amid concern that recipients of certain blood transfusions may risk infection with a deadly protein responsible for the human form of mad cow disease, researchers in Canada now report development of a special filter that quickly and effectively removes the protein from blood.In addition to causing m read more Sat Apr 2008 Sat Apr 2008

Cells On Path To Becoming Mature T Cells More Flexible Than Commonly Thought

Categorie : Blood / Hematology
Contrary to the currently accepted model of T-cell development, researchers at the University of Pennsylvania School of Medicine have found that juvenile cells on their way to becoming mature immune cells can develop into either T cells or other blood-cell types versus only being committed to the T- ...

read more Contrary to the currently accepted model of T-cell development, researchers at the University of Pennsylvania School of Medicine have found that juvenile cells on their way to becoming mature immune cells can develop into either T cells or other blood-cell types versus only being committed to the T- read more Sat Apr 2008 Sat Apr 2008

New Data Show Revlimid(R) (lenalidomide) Offers Significant Survival Gainsfor People With Life-limiting Blood Cancer

Categorie : Blood / Hematology
According to data presented today at the 48th Annual Scientific Meeting of the British Society for Haematology (BSH), patients taking Revlimid® (lenalidomide) plus high dose dexamethasone for treatment of multiple myeloma experience a significant survival gain. On average, patients experienced nearl ...

read more According to data presented today at the 48th Annual Scientific Meeting of the British Society for Haematology (BSH), patients taking Revlimid® (lenalidomide) plus high dose dexamethasone for treatment of multiple myeloma experience a significant survival gain. On average, patients experienced nearl read more Sat Apr 2008 Sat Apr 2008

Gore Revise Study Receives Approval From FDA

Categorie : Blood / Hematology
FDA approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with Viabahn® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates (Gore). The Gore REVISE Study is a randomized, multi-center clinical trial intended to establish efficacy ...

read more FDA approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with Viabahn® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates (Gore). The Gore REVISE Study is a randomized, multi-center clinical trial intended to establish efficacy read more Sat Apr 2008 Sat Apr 2008

FDA Reports More Deaths Linked To Contaminated Heparin

Categorie : Blood / Hematology
The US Food and Drug Administration released an update yesterday, 8th April, showing a dramatic rise in the number of deaths that may be due to patients having allergic reactions to contaminated heparin. The agency puts the new figure at 62 deaths in the last 15 months, which is considerably more t ...

read more The US Food and Drug Administration released an update yesterday, 8th April, showing a dramatic rise in the number of deaths that may be due to patients having allergic reactions to contaminated heparin. The agency puts the new figure at 62 deaths in the last 15 months, which is considerably more t read more Sat Apr 2008 Sat Apr 2008

DSMB Supports Continuation Of Anthera Phase II Impacts Trial For The Prevention Of Acute Chest Syndrome In Patients With Sickle Cell Disease

Categorie : Blood / Hematology
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has recommended that Anthera's Phase II clini ...

read more Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has recommended that Anthera's Phase II clini read more Sat Apr 2008 Sat Apr 2008

Sunesis Pharmaceuticals Reports Data From Nonclinical Studies Of SNS-032 At The Annual Meeting Of The American Association For Cancer Research

Categorie : Blood / Hematology
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) reported data from nonclinical studies of SNS-032 in multiple myeloma and mantle cell lymphoma. Data from studies conducted in collaboration with the Multiple Myeloma Research Consortium (MMRC) and with the University of Texas MD Anderson Cancer Center ...

read more Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) reported data from nonclinical studies of SNS-032 in multiple myeloma and mantle cell lymphoma. Data from studies conducted in collaboration with the Multiple Myeloma Research Consortium (MMRC) and with the University of Texas MD Anderson Cancer Center read more Sat Apr 2008 Sat Apr 2008

SPL Responds To FDA Commissioner's Speculation That Motive For The Contamination Of Heparin May Have Been Economic Fraud

Categorie : Blood / Hematology
FDA Commissioner von Eschenbach speculated that the motive for the contamination of heparin may have been economic fraud. He could not have been referring to Scientific Protein Laboratories (SPL) or Changzhou SPL when he made this statement. Based upon testing and reports from around the world, it ...

read more FDA Commissioner von Eschenbach speculated that the motive for the contamination of heparin may have been economic fraud. He could not have been referring to Scientific Protein Laboratories (SPL) or Changzhou SPL when he made this statement. Based upon testing and reports from around the world, it read more Sat Apr 2008 Sat Apr 2008

Medgenics On Target To Start Phase I/II Clinical Trials With EPODURE Protein Therapy For Anaemia Mid-2008 As Planned

Categorie : Blood / Hematology
Medgenics (AIM:MEDG), the US-incorporated biopharmaceutical company, is pleased to provide an update on progress towards the start of its Phase I/II clinical trials with EPODURE, its lead sustained-action protein therapy for producing and delivering erythropoietin (EPO) to treat anaemia. The Company ...

read more Medgenics (AIM:MEDG), the US-incorporated biopharmaceutical company, is pleased to provide an update on progress towards the start of its Phase I/II clinical trials with EPODURE, its lead sustained-action protein therapy for producing and delivering erythropoietin (EPO) to treat anaemia. The Company read more Sat Apr 2008 Sat Apr 2008

Semafore's PI3 Kinase Inhibitor SF1126 Is A Vascular Targeted Conjugate In Phase I Clinical Trials In Solid Tumors And Multiple Myeloma

Categorie : Blood / Hematology
Semafore Pharmaceuticals Inc. announced on the occasion of a poster presentation at the 2008 AACR Annual Meeting that its integrin-targeted PI3 kinase inhibitor, SF1126, was shown to cause significant tumor regression in combination with rapamycin in a renal cell carcinoma mouse model. The combinati ...

read more Semafore Pharmaceuticals Inc. announced on the occasion of a poster presentation at the 2008 AACR Annual Meeting that its integrin-targeted PI3 kinase inhibitor, SF1126, was shown to cause significant tumor regression in combination with rapamycin in a renal cell carcinoma mouse model. The combinati read more Sat Apr 2008 Sat Apr 2008

<<< previous | 1 | 2 | 3 | 4 | 5 next >>>